Clinuvel

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The company is committed to developing drugs for the treatment of a range of severe skin diseases. Its main compound, SCENESSE (afamelanotide 16 mg), prevents phototoxicity (allergic reactions and burns) in patients with erythropoietic protoporphyria (EPP). The company focuses on preventing symptoms of skin diseases associated with exposure to harmful ultraviolet (UV) radiation, as well as skin pigmentation disorders caused by various pigmentary conditions. SCENESSE has completed Phase II and Phase III trials in the United States and Europe and has received marketing authorization from the European Commission for adult EPP. It operates in Europe, the United States, and Singapore. SCENESSE works by increasing melanin levels in the skin and protecting against ultraviolet radiation (UVR) and sunlight.